Antonio Waldo Zuardi
Antonio Waldo Zuardi
Professor, School of Medicine of Ribeirão Preto, University of São Paulo
Verified email at fmrp.usp.br
TitleCited byYear
Action of cannabidiol on the anxiety and other effects produced by δ9-THC in normal subjects
AW Zuardi, I Shirakawa, E Finkelfarb, IG Karniol
Psychopharmacology 76 (3), 245-250, 1982
5301982
Opposite effects of Δ-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology
S Bhattacharyya, PD Morrison, P Fusar-Poli, R Martin-Santos, ...
Neuropsychopharmacology 35 (3), 764, 2010
4262010
Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug
AW Zuardi, JAS Crippa, JEC Hallak, FA Moreira, FS Guimarães
Brazilian journal of medical and biological research 39 (4), 421-429, 2006
4022006
Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients
MM Bergamaschi, RHC Queiroz, MHN Chagas, DCG De Oliveira, ...
Neuropsychopharmacology 36 (6), 1219, 2011
3322011
Distinct effects of Δ9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing
P Fusar-Poli, JA Crippa, S Bhattacharyya, SJ Borgwardt, P Allen, ...
Archives of general psychiatry 66 (1), 95-105, 2009
3312009
History of cannabis as a medicine: a review
AW Zuardi
Brazilian Journal of Psychiatry 28 (2), 153-157, 2006
3162006
Cannabis and anxiety: a critical review of the evidence
JA Crippa, AW Zuardi, R Martín‐Santos, S Bhattacharyya, Z Atakan, ...
Human Psychopharmacology: Clinical and Experimental 24 (7), 515-523, 2009
3102009
Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action
AW Zuardi
Brazilian Journal of Psychiatry 30 (3), 271-280, 2008
3002008
Alcohol Use Disorders Identification Test (AUDIT): An updated systematic review of psychometric properties.
C de Meneses-Gaya, AW Zuardi, SR Loureiro, JAS Crippa
Psychology & Neuroscience 2 (1), 83, 2009
2522009
Antianxiety effect of cannabidiol in the elevated plus-maze
FS Guimarães, TM Chiaretti, FG Graeff, AW Zuardi
Psychopharmacology 100 (4), 558-559, 1990
2331990
Safety and side effects of cannabidiol, a Cannabis sativa constituent
M Machado Bergamaschi, R Helena Costa Queiroz, A Waldo Zuardi, ...
Current drug safety 6 (4), 237-249, 2011
2312011
Antipsychotic effect of cannabidiol.
AW Zuardi, SL Morais, FS Guimarães, R Mechoulam
The Journal of clinical psychiatry, 1995
2271995
Effects of ipsapirone and cannabidiol on human experimental anxiety
AW Zuardi, RA Cosme, FG Graeff, FS Guimarães
Journal of psychopharmacology 7 (1_suppl), 82-88, 1993
2101993
Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report
JAS Crippa, GN Derenusson, TB Ferrari, L Wichert-Ana, FLS Duran, ...
Journal of psychopharmacology 25 (1), 121-130, 2011
2062011
Cannabidiol for the treatment of psychosis in Parkinson’s disease
AW Zuardi, JAS Crippa, JEC Hallak, JP Pinto, MHN Chagas, ...
Journal of Psychopharmacology 23 (8), 979-983, 2009
1952009
Effects of cannabidiol (CBD) on regional cerebral blood flow
JA de Souza Crippa, AW Zuardi, GEJ Garrido, L Wichert-Ana, R Guarnieri, ...
Neuropsychopharmacology 29 (2), 417, 2004
1952004
Escalas de avaliação clínica em psiquiatria e psicofarmacologia
C Gorenstein, LHSG Andrade, AW Zuardi
1832000
Cannabidiol monotherapy for treatment-resistant schizophrenia
AW Zuardi, JEC Hallak, SM Dursun, SL Morais, RF Sanches, RE Musty, ...
Journal of Psychopharmacology 20 (5), 683-686, 2006
1702006
Effects of cannabidiol in animal models predictive of antipsychotic activity
AW Zuardi, JA Rodrigues, JM Cunha
Psychopharmacology 104 (2), 260-264, 1991
1671991
Induction of psychosis byδ9-tetrahydrocannabinol reflects modulation of prefrontal and striatal function during attentional salience processing
S Bhattacharyya, JA Crippa, P Allen, R Martin-Santos, S Borgwardt, ...
Archives of general psychiatry 69 (1), 27-36, 2012
1492012
The system can't perform the operation now. Try again later.
Articles 1–20